Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
British Journal of Cancer|December 2, 2010
Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivoF R Lamont, D C Tomlinson, P A Cooper, et al.
Journal of Tropical Pediatrics|November 15, 2000
Serial interleukin 6 measurements in the early diagnosis of neonatal sepsisM O Magudumana, D E Ballot, P A Cooper, et al.
Anticancer Research|May 23, 2002
Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo anti vascular effects in experimental tumoursS E Holwell, P A Cooper, K Grosios, et al.
Cancer Research|December 16, 1998
Angiogenesis in the hollow fiber tumor model influences drug delivery to tumor cells: implications for anticancer drug screening programsR M Phillips, J Pearce, P M Loadman, et al.
Lancet (London, England)|December 14, 1985
Effect of early neurodevelopmental therapy in normal and at-risk survivors of neonatal intensive careM Goodman, A D Rothberg, J E Houston-McMillan, et al.
Archiv Der Pharmazie|July 26, 2000
Synthesis and antitumour activity of new derivatives of flavone-8-acetic acid (FAA). Part 4: Variation of the basic structureR A Aitken, M C Bibby, P A Cooper, et al.
Clinical & Experimental Metastasis|January 29, 2000
Chemokines induce the cellular migration of MCF-7 human breast carcinoma cells: subpopulations of tumour cells display positive and negative chemotaxis and differential in vivo growth potentialsS J Prest, R C Rees, C Murdoch, et al.
Anticancer Research|January 30, 2003
Anti-tumor and anti-vascular effects of the novel tubulin-binding agent combretastatin A-1 phosphateS E Holwell, P A Cooper, M J Thompson, et al.
Cancer Gene Therapy|August 13, 2011
Adenovirus-mediated hypoxia-targeted gene therapy using HSV thymidine kinase and bacterial nitroreductase prodrug-activating genes in vitro and in vivoT J Harvey, I M Hennig, S D Shnyder, et al.
Gene Therapy|April 23, 2010
Retargeted adenoviral cancer gene therapy for tumour cells overexpressing epidermal growth factor receptor or urokinase-type plasminogen activator receptorT J Harvey, D Burdon, L Steele, et al.
Pageof 8